Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Neoplasm Metastasis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thyroid Neoplasms 1 Sarcoma 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Endometrial Adenocarcinoma 1 Carcinoma, Medullary 1

Interventions

Radiotherapy 9 Radiosurgery 6 Oxaliplatin 5 Cisplatin 5 Paclitaxel 4 Capecitabine 4 Leucovorin 3 Fluorouracil 3 Doxorubicin 3 Docetaxel 3 regorafenib 2 pembrolizumab 2 enzalutamide 2 Temozolomide 2 Radiofrequency Ablation 2 Mitomycin 2 Irinotecan 2 Ifosfamide 2 Gemcitabine 2 Filgrastim 2 Bleomycin 2 Bevacizumab 2 Analgesia 2 Albumin-Bound Paclitaxel 2 trifluridine tipiracil drug combination 1 spartalizumab 1 sargramostim 1 plozalizumab 1 palbociclib 1 orteronel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡